Voltar
Artigo Acesso aberto Revisado por pares
BIBTEX RIS

Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline BRCA/PALB2 Mutation

2020; Lippincott Williams & Wilkins; Volume: 38; Issue: 13 Linguagem: Inglês

10.1200/jco.19.02931

ISSN

1527-7755

Autores

Eileen M. O’Reilly, Jonathan W. Lee, Mark M. Zalupski, Marinela Capanu, Jennifer Park, Talia Golan, Esther Tahover, Maeve A. Lowery, Joanne F. Chou, Vaibhav Sahai, Robin Brenner, Hedy L. Kindler, Kenneth H. Yu, Alice Zervoudakis, Shreya Vemuri, Zsofia K. Stadler, Richard Kinh Gian, Neesha C. Dhani, Alice Chen, David P. Kelsen,

Tópico(s)

PARP inhibition in cancer therapy

Resumo

Five percent to 9% of pancreatic ductal adenocarcinomas (PDACs) develop in patients with a germline

Referência(s)